

Cancer Association of South Africa (CANSA)



Research • Educate • Support

Fact Sheet On Hodgkin's Lymphoma

Introduction

Lymphoma is a type of cancer involving cells of the immune system, called lymphocytes. Just as cancer represents many different diseases, lymphoma represents many different cancers of lymphocytes – about 35 different subtypes.

The Lymphatic System

The lymphatic system is an extensive drainage network that helps keep bodily fluid levels in balance and defends the body against infections. It is made up of a network of lymphatic vessels that carry lymph - a clear, watery fluid that contains protein molecules, salts, glucose, urea, and other substances - throughout the body.

The spleen, which is located in the upper left part of the abdomen under the ribcage, works as part of the lymphatic system to protect the body, clearing worn out red blood cells and other foreign bodies from the bloodstream to help fight off infection.

[Picture Credit: Lymphatic System]

One of the lymphatic system's major jobs is to collect extra lymph fluid from body tissues and return it to the blood. This process is crucial because water, proteins, and other substances are continuously leaking out of tiny blood capillaries into the surrounding body tissues. If the lymphatic system did not drain the excess




Diagram of the lymphatic system
Copyright © CancerHelp UK


Researched and Authored by Prof Michael C Herbst
[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

October 2020

fluid from the tissues, the lymph fluid would build up in the body's tissues, and the tissue would swell.

The lymphatic system also helps defend the body against germs like viruses, bacteria, and fungi that can cause illnesses. Those germs are filtered out in the lymph nodes, small masses of tissue located along the network of lymph vessels. The nodes house lymphocytes, a type of white blood cell. Some of those lymphocytes make antibodies, special proteins that fight off germs and stop infections from spreading by trapping disease-causing germs and destroying them.



[Picture Credit – Lymph Node]

The spleen also helps the body fight infection. The spleen contains lymphocytes and another kind of white blood cell called macrophages, which engulf and destroy bacteria, dead tissue, and foreign matter and remove them from the blood passing through the spleen.

Types of Lymphoma

Lymphomas fall into one of two major categories:

- Hodgkin's lymphoma (HL, previously called Hodgkin's disease)
- Non-Hodgkin's Lymphoma (NHL, all other lymphomas)

These two types occur in the same places, may be associated with the same symptoms, and often have similar appearance on physical examination. However, they are readily distinguishable via microscopic examination.

Hodgkin's lymphoma develops from a specific abnormal B lymphocyte lineage. NHL may derive from either abnormal B or T cells and are distinguished by unique genetic markers. There are five subtypes of Hodgkin's lymphoma and about 30 subtypes of non-Hodgkin's lymphoma.

Hodgkin's Lymphoma

Hodgkin's lymphoma is a cancer of lymph tissue found in the lymph nodes, spleen, liver, bone marrow, and other sites.

Kaseb, H. & Babiker, H.M. 2020.

“Hodgkin lymphoma (HL), formerly called Hodgkin's disease, is a rare monoclonal lymphoid neoplasm with high cure rates. Biological and clinical studies have divided this disease entity into two distinct categories: classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL). These two disease entities show differences in the clinical picture and pathology. Classical Hodgkin lymphoma accounts for approximately 95% of all HL, and it is further subdivided into four subgroups: nodular sclerosis (NSHL), lymphocyte-rich (LRHL), mixed cellularity

(MCHL), and lymphocyte-depleted (LDHL). Four features characterize Hodgkin lymphomas. They commonly arise in the cervical lymph nodes; the disease is more common in young adults; there are scattered large mononuclear Hodgkin and multinucleated cells (Reed-Sternberg) intermixed in a background of a mixture of non-neoplastic inflammatory cells; finally, T lymphocytes are often observed surrounding the characteristic neoplastic cells. Hodgkin lymphoma has an excellent overall prognosis with approximately an 80% cure rate.”

Incidence Hodgkin’s Lymphoma in South Africa

According to the National Cancer Registry (2016) the following number of Hodgkin’s Lymphoma cases was histologically diagnosed in South Africa during 2016. Histologically diagnosed means that a tissue sample (biopsy) was forwarded to an approved laboratory where a specially trained pathologist confirmed the cancer diagnosis:

| Group - Males 2016 | Actual No of Cases | Estimated Lifetime Risk | Percentage of All Cancers |
|-----------------------|-----------------------|----------------------------|------------------------------|
| All males | 366 | 1:845 | 0,94% |
| Asian males | 17 | 1:511 | 1,74% |
| Black males | 246 | 1:1 049 | 1,85% |
| Coloured males | 35 | 1:977 | 0,76% |
| White males | 68 | 1:441 | 0,32% |

| Group - Females 2016 | Actual No of Cases | Estimated Lifetime Risk | Percentage of All Cancers |
|-------------------------|-----------------------|----------------------------|------------------------------|
| All females | 277 | 1:1 269 | 0,66% |
| Asian females | 11 | 1:861 | 0,88% |
| Black females | 174 | 1:1 613 | 0,88% |
| Coloured females | 28 | 1:1 212 | 0,56% |
| White females | 64 | 1:493 | 0,39% |

The frequency of histologically diagnosed cases of Hodgkin’s Lymphoma in South Africa for 2016 was as follows (National Cancer Registry, 2016):

| Group - Males 2016 | 0 – 19 Years | 20 – 29 Years | 30 – 39 Years | 40 – 49 Years | 50 – 59 Years | 60 – 69 Years | 70 – 79 Years | 80+ Years |
|-----------------------|-----------------|------------------|------------------|------------------|------------------|------------------|------------------|--------------|
| All males | 73 | 51 | 82 | 85 | 39 | 23 | 11 | 2 |
| Asian males | 0 | 3 | 3 | 6 | 0 | 3 | 2 | 0 |
| Black males | 58 | 33 | 57 | 68 | 22 | 7 | 1 | 0 |
| Coloured males | 4 | 8 | 11 | 11 | 6 | 2 | 1 | 1 |
| White males | 11 | 7 | 11 | 9 | 11 | 11 | 7 | 1 |

| Group - Females 2016 | 0 – 19 Years | 20 – 29 Years | 30 – 39 Years | 40 – 49 Years | 50 – 59 Years | 60 – 69 Years | 70 – 79 Years | 80+ Years |
|-------------------------|-----------------|------------------|------------------|------------------|------------------|------------------|------------------|--------------|
| All females | 26 | 57 | 86 | 51 | 27 | 17 | 11 | 2 |
| Asian females | 2 | 3 | 3 | 1 | 1 | 1 | 0 | 0 |
| Black females | 14 | 35 | 59 | 39 | 16 | 10 | 1 | 0 |
| Coloured females | 4 | 7 | 8 | 3 | 2 | 1 | 3 | 0 |
| White females | 6 | 12 | 16 | 8 | 8 | 5 | 7 | 2 |

N.B. In the event that the totals in any of the above tables do not tally, this may be the result of uncertainties as to the age, race or sex of the individual. The totals for ‘all males’ and ‘all females’, however, always reflect the correct totals.

Researched and Authored by Prof Michael C Herbst
[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

Causes and Risk Factors of Hodgkin's Lymphoma

The cause of Hodgkin's Lymphoma is not known. Hodgkin's lymphoma is most common among individuals aged 15 - 35 and 50 - 70. Past infection with the Epstein-Barr virus (EBV) is thought to contribute to some cases. Patients with HIV infection are also said to be more at risk than the general population.

Risk Factors

Factors that may increase the risk of Hodgkin's lymphoma include:

- Age - Hodgkin's lymphoma is most often diagnosed in people between the ages of 15 and 35, as well as those older than 55
- A family history of lymphoma - anyone with a brother or a sister who has Hodgkin's lymphoma has an increased risk of developing Hodgkin's lymphoma. Studies also show up to a seven-fold increased risk in people with a parent or sibling diagnosed with Hodgkin's lymphoma or with any blood or lymphatic cancer
- Sex - males are slightly more likely to develop Hodgkin's lymphoma
- Past Epstein-Barr infection - individuals who have had illnesses caused by the Epstein-Barr virus, such as infectious mononucleosis, are more likely to develop Hodgkin's lymphoma
- A weakened immune system - having a compromised immune system, such as from HIV/AIDS or from having an organ transplant requiring medications to suppress the immune response, increases the risk of Hodgkin's lymphoma.

Symptoms of Hodgkin's Lymphoma

The following symptoms may present:

- Fatigue
- Fever and chills that come and go
- Itching all over the body that cannot be explained
- Loss of appetite
- Soaking night sweats
- Painless swelling of the lymph nodes in the neck, armpits, or groin (swollen glands)
- Weight loss that cannot be explained

[Picture Credit: Hodgkin's Lymphoma]

Other symptoms that may occur:

- Coughing, chest pains, or breathing problems if there are swollen lymph nodes in the chest
- Excessive sweating
- Pain or feeling of fullness below the ribs due to swollen spleen or liver
- Pain in lymph nodes after drinking alcohol
- Skin blushing or flushing



Note: Symptoms caused by Hodgkin's lymphoma

Researched and Authored by Prof Michael C Herbst
[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

October 2020

may also occur with other conditions. One should consult a doctor about the meaning of specific symptoms.

Signs and Tests

The first sign of Hodgkin's lymphoma is often a swollen lymph node, which appears without a known cause. The disease can spread to nearby lymph nodes. Later it may spread to the spleen, liver, bone marrow, or other organs.

Piris, M.A., Medeiros, L.J. & Chang, K-C. 2020.

“Hodgkin lymphoma (HL) is composed of two distinct pathological entities, nodular lymphocyte predominant HL and classic HL, the latter with four subtypes. In contrast with most other human lymphomas, in which the neoplastic cells are a major population of the tumour constituents, the neoplastic 'Hodgkin (H) and Reed-Sternberg (RS)' cells usually account for less than 10% of tumour bulk against an inflammatory background. The neoplastic cells of HL are of B-cell lineage (PAX5+) in virtually all cases. HL usually affects young patients with a localised nodal disease and its clinical behaviour is typically indolent. Patients respond well to chemotherapy with cure rates of 80-90% and the recent finding of PD-L1 expression, an immune checkpoint, warrants the use of immunotherapy for some patients with recurrent and/or refractory HL. The enigmatic RS cells of HL are unique in their abundant cytoplasm and characteristic bilobed nuclei with eosinophilic prominent nucleoli, imparting an 'owl-eye' appearance. H cells are mononuclear variants. The viral inclusion-like morphology was a clue on the way to discovering an association between classic HL and Epstein-Barr virus (EBV). However, this association is variable in different geographic regions and in pathological subtypes, and correlates with older age (>60 years) and socioeconomic status, indicating that environmental factors are likely involved in HL pathogenesis. Virus-associated endoplasmic reticulum (ER) stress also may contribute to mechanisms underlying the characteristic morphological features of HRS cells. ER stress has been found to induce aberrant, cytoplasmic cyclin A expression, leading to nuclear hyperdiploidy. Aberrant expression of cyclin A is commonly associated with HRS cell morphology in HL, probably through EBV-latent membrane protein-1 (LMP1) signalling. Shelterin also may play a role in the morphogenesis of multinucleated RS cells. In addition, EBV-positive and -negative HL cases express survival, but not death signals of ER stress at similar levels and EBV-LMP1 transfection increases expression of survival signals in HL cell lines. These data suggest that surviving ER stress may be involved in HL pathogenesis.”

The disease may be diagnosed after:

- Biopsy of suspected tissue, usually a lymph node biopsy
- Bone marrow biopsy

Spina, V. & Rossi, D. 2019.

“In the era of personalised medicine, genetic information is critical to directing therapeutic options, aiding risk stratification and disease monitoring of lymphomas. Liquid biopsy is a novel noninvasive, real-time and tumour-specific technique, reliably reflecting the comprehensive tumour genetic profile, and thus holds great promise for the genetic assessment, response monitoring and relapse detection of lymphomas. Standard methods for disease response assessment in patients with lymphoma, including positron emission tomography, are imperfect. In other haematological malignancies, particularly leukaemias, the ability to detect minimal residual disease (MRD) is

increasingly influencing treatment paradigms. However, in some subtypes of lymphoma, such as diffuse large B-cell lymphoma and classic Hodgkin's lymphoma, the application of MRD assessment techniques such as flow cytometry or polymerase chain reaction-based methods has been challenged by the absence of circulating disease. The review summarises the applications of liquid biopsy in the assessment of tumour burden and response to therapy, noninvasive genomic profiling, and monitoring of clonal dynamics in patients with diffuse large B-cell lymphoma and classic Hodgkin's lymphoma."

The following procedures may also be done:

- Blood chemistry tests including protein levels, liver function tests, kidney function tests, and uric acid level
- Bone marrow biopsy
- CT scans of the chest, abdomen, and pelvis
- Complete blood count (CBC) to check for anaemia and white blood count
- PET scan

Ansell, S.M. 2015.


"Hodgkin lymphoma is a rare B-cell malignant neoplasm affecting approximately 9000 new patients annually. This disease represents approximately 11% of all lymphomas seen in the United States and comprises 2 discrete disease entities--classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Within the subcategorization of classical Hodgkin lymphoma are defined subgroups: nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich Hodgkin lymphoma. Staging of this disease is essential for the choice of optimal therapy. Prognostic models to identify patients at high or low risk for recurrence have been developed, and these models, along with positron emission tomography, are used to provide optimal therapy. The initial treatment for patients with Hodgkin lymphoma is based on the histologic characteristics of the disease, the stage at presentation, and the presence or absence of prognostic factors associated with poor outcome. Patients with early-stage Hodgkin lymphoma commonly receive combined-modality therapies that include abbreviated courses of chemotherapy followed by involved-field radiation treatment. In contrast, patients with advanced-stage Hodgkin lymphoma commonly receive a more prolonged course of combination chemotherapy, with radiation therapy used only in selected cases. For patients with relapse or refractory disease, salvage chemotherapy followed by high-dose treatment and an autologous stem cell transplant is the standard of care. For patients who are ineligible for this therapy or those in whom high-dose therapy and autologous stem cell transplant have failed, treatment with brentuximab vedotin is a standard approach. Additional options include palliative chemotherapy, immune checkpoint inhibitors, nonmyeloablative allogeneic stem cell transplant, or participation in a clinical trial testing novel agents."

Staging of Hodgkin's Lymphoma

The doctor considers the following to determine the stage of Hodgkin's lymphoma:

- The number of lymph nodes that have Hodgkin lymphoma cells
- Whether these lymph nodes are on one or both sides of the diaphragm (see picture)
- Whether the disease has spread to the bone marrow, spleen, liver, or lung.

Staging is important as it assists the doctor to determine treatment.



Treatment of Hodgkin's Lymphoma

Treatment of Hodgkin's Lymphoma may include:

Targeted Therapy - newer drugs that work differently from standard chemo drugs are currently being studied.

Monoclonal antibodies - antibodies are proteins normally made by the immune system to help fight infections. Each antibody attacks only a specific target (usually a protein on the surface of an unwanted cell).

Immunotherapy - also called biologic therapy, is designed to boost the body's natural defenses to fight the cancer.

Gene profiling - some researchers are looking at the specific genes and proteins that are found in Hodgkin's lymphoma. These genes and proteins provide more information about the behaviour of Hodgkin's lymphoma, which may help better target the lymphoma with chemotherapy or immunotherapy.

Other treatments that may be considered - stem cell transplantation is being studied in combination with chemotherapy and immunotherapy regimens for new or recurrent Hodgkin's lymphoma. Mini-allogeneic, also called non-myeloablative or reduced intensity transplant, and allogeneic transplantation are being tested in combination with chemotherapy and immunotherapy for new or recurrent Hodgkin lymphoma.

Palliative care - clinical trials are underway to find better ways of reducing symptoms and side effects of current Hodgkin's lymphoma treatments in order to improve patients' comfort and quality of life.

Chemotherapy - Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team.

Matsuki, E. & Younes, A. 2016.

"Treatment for relapsed/refractory (R/R) Hodgkin and non-Hodgkin lymphoma remains challenging. The introduction of rituximab to B cell non-Hodgkin lymphoma (B-NHL) treatment significantly improved patients' response rate and survival; however, approximately one third of patients with diffuse large B cell lymphoma, the most common B-NHL subtype, still have a relapse or become refractory after first-line therapy. More recently, antibody therapies and small-molecule inhibitors were approved for treating R/R lymphomas; these agents include brentuximab vedotin, ibrutinib, and idelalisib. Immune checkpoint inhibitors and other immune therapies are emerging treatments currently being evaluated in various clinical trials for their efficacy against lymphoid malignancies. Striking results from these treatment modalities have been observed in solid tumors, and evidence is accumulating to support their use in various lymphomas. The most exciting results from immune checkpoint inhibitor therapy have been seen in patients with R/R Hodgkin lymphoma, in whom the overall response rate has reached 60-80 %. Results in NHL are more similar to those seen in other solid malignancies, ranging between 20 and 40 %, depending on the histology. Formal approval of these drugs is being awaited, as are the results of combination therapy with checkpoint inhibitors and other treatment modalities, including conventional chemotherapy, small-molecule inhibitors, and other immune therapies. Although response rates have been promising, attention must be paid to the management of unique immune-related adverse events, which warrant close monitoring in some cases. Identification of biomarkers that predict response or severe adverse events using either the tumor specimen or peripheral blood would aid in selecting patients suited for these types of treatment as well as determining the ideal sequence of treatment within the realm of immune therapies."

Treatment of Older Patients

Evens, A.M., Carter, J., Loh, K.P. & David, K.A. 2019.

"Hodgkin lymphoma (HL) in older patients, commonly defined as ≥ 60 years of age, is a disease for which survival rates have historically been significantly lower compared with younger patients. Older HL patients appear to have different disease biology compared with younger patients, including increased incidence of mixed cellularity histology, Epstein-Barr virus-related, and advanced-stage disease. For prognostication, several studies have documented the significance of comorbidities and functional status in older HL patients, as well as the importance of achieving initial complete remission. Collectively, selection of therapy for older HL patients should be based in part on functional status, including pretreatment assessment of activities of daily living (ADL), comorbidities, and other geriatric measures (eg, cognition, social support). Treatment of fit older HL patients should

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

October 2020

be given with curative intent, regardless of disease stage. However, attention should be paid to serious treatment-related toxicities, including risk of treatment-related mortality. Although inclusion of anthracycline therapy is important, bleomycin-containing regimens (eg, doxorubicin, bleomycin, vinblastine, dacarbazine) may lead to prohibitive pulmonary toxicity, and intensive therapies (eg, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) are too toxic. Brentuximab vedotin given sequentially before and after doxorubicin, vinblastine, and dacarbazine to fit, untreated advanced-stage older HL patients was recently shown to be tolerable and highly effective. Therapy for patients who are unfit or frail because of comorbidities and/or ADL loss is less clear and should be individualized with consideration of lower-intensity therapy, such as brentuximab vedotin with or without dacarbazine. Altogether, therapy for older HL patients should be tailored based upon a geriatric assessment, and novel targeted agents should continue to be integrated into treatment paradigms.”

Complications of Hodgkin’s Lymphoma

Treatments for Hodgkin's lymphoma may have complications. Long-term complications of chemotherapy or radiation therapy may include:

- Bone marrow diseases (such as leukaemia)
- Heart disease
- Inability to have children (infertility)
- Lung problems
- Other cancers
- Thyroid problems

Frick, M.A., Vachani, C.C., Hampshire, M.K., Bach, C., Arnold-Korzeniowski, K., Metz, J.M. & Hill-Kayzer, C.E. 2018.

PURPOSE: Multimodal treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) yields excellent outcomes; however, survivors are at risk of developing myriad late and long-term effects.

METHODS: From a convenience sample of 964 survivors of HL (37%) and NHL (63%) using a publicly available Internet-based survivorship care plan (SCP) tool between 2011 and 2016, we examined patient-reported cancer care, toxicities, and survivorship care data.

RESULTS: Of all survivors, 67% were female and 84% were white and 88% were free of cancer. Median age of diagnosis was 28 years for survivors of HL and 49 years for NHL. Many survivors reported treatment with chemotherapy (92%), surgery (52%), and/or radiation (41%), with most radiation delivered to chest/mantle fields (81%). Survivors reported a diversity of radiation- and chemotherapy-related sequelae, including thyroid dysfunction, speaking and/or swallowing changes, pulmonary fibrosis/pneumonitis, heart disease, chronic fatigue, neurocognitive decline, neuropathy, sexual changes, and secondary breast cancers. Few reported receipt of previous survivorship information. Most reported management/comanagement by an oncology specialist after active treatment; however, a shift to management by primary care provider alone was observed as a trend over time in follow-up. Sixty-six percent of users who responded to a follow-up survey reported that they intend to share the SCP with their health care team.

CONCLUSION: Survivors of lymphoma, many of whom are free of disease, report a substantial burden of late and long-term adverse effects, suboptimal delivery of survivorship information, and transitions of care in follow-up in which fragmented systems and/or poor communication may contribute to unmet survivor needs. Multiple opportunities thus exist for which SCPs may be used to

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

October 2020

improve awareness regarding survivorship and associated adverse effects in addition to communicating follow-up care plans between survivors and treatment teams.

About Clinical Trials

Clinical trials are research studies that involve people. They are conducted under controlled conditions. Only about 10% of all drugs started in human clinical trials become an approved drug.

Clinical trials include:

- Trials to test effectiveness of new treatments
- Trials to test new ways of using current treatments
- Tests new interventions that may lower the risk of developing certain types of cancers
- Tests to find new ways of screening for cancer

The [South African National Clinical Trials Register](#) provides the public with updated information on clinical trials on human participants being conducted in South Africa. The Register provides information on the purpose of the clinical trial; who can participate, where the trial is located, and contact details.

For additional information, please visit: www.sanctr.gov.za/

Medical Disclaimer

This Fact Sheet is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this Fact Sheet. So far as permissible by law, the Cancer Association of South Africa (CANSA) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this Fact Sheet.

Whilst CANSA has taken every precaution in compiling this Fact Sheet, neither it, nor any contributor(s) to this Fact Sheet can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this Fact Sheet.



Sources and References Consulted or Utilised

American Cancer Society

<http://www.cancer.org/Cancer/Non-HodgkinLymphoma/DetailedGuide/non-hodgkin-lymphoma-risk-factors>
<http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-new-research>

Ansell, S.M. 2015. Hodgkin Lymphoma: diagnosis and treatment. *Mayo Clin Proc.* 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005.

Autologous Transplant

<http://multiple-sclerosis-research.blogspot.com/p/grand-challenges-in-ms.html>

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

October 2020

Boston Children's Hospital

<http://childrenshospital.org/az/Site2182/mainpageS2182P1.html>

Cancer.Net

<http://www.cancer.net/cancer-types/lymphoma-hodgkin/latest-research>

Cancer Research UK

<http://www.cancerresearchuk.org/cancer-info/cancerstats/types/hodgkinslymphoma/riskfactors/hodgkins-lymphoma-risk-factors#genetics>

Cancer Therapy Advisor

<http://www.cancertherapyadvisor.com/>

Cells of the Immune System

http://www.alohamedicinals.com/how-your-immune-system-works.html#.VBvpG_mSySo

eMedicineHealth. Lymphoma. http://www.emedicinehealth.com/lymphoma/article_em.htm

Frick, M.A., Vachani, C.C., Hampshite, M.K., Bach, C., Arnold-Korzeniowski, K., Metz, J.M. & Hill-Kayzer, C.E. 2018. Patient-reported survivorship care practices and late effects after treatment of Hodgkin and non-Hodgkin Lymphoma. *JCO Clin Cancer Inform.* 2018 Dec;2:1-10. doi: 10.1200/CCI.18.00015.

Evens, A.M., Carter, J., Loh, K.P. & David, K.A. 2019. Management of older Hodgkin lymphoma patients. *Hematology Am Soc Hematol Educ Program.* 2019 Dec 6;2019(1):233-242.

Hodgkin's Lymphoma

https://www.google.co.za/search?q=hodgkin%27s+lymphoma&source=lnms&tbn=isch&sa=X&ei=Kl-ZU_bUJaeV7Ab_q4CwCA&sqi=2&ved=0CAYQ_AUoAQ&biw=1517&bih=714&dpr=0.9#facrc=_&imgdii=wrUKxr_raB8ehM%3A%3B3MTF6fAZjSVIEM%3BwrUKxr_raB8ehM%3A&imgrc=wrUKxr_raB8ehM%253A%3ByWB-1qzXMW4rDM%3Bhttp%253A%252F%252Fs2.hubimg.com%252Fu%252F6438913_f260.jpg%3Bhttp%253A%252F%252Fki.mhdimino.blogspot.com%252F2013%252F03%252Fhodgkins-disease-overview.html%3B260%3B195

Kaseb, H. & Babiker, H.M. 2020. Hodgkin Lymphoma. *In: StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. 2020 Jun 30.

KidsHealth. The Lymphatic System. http://kidshealth.org/parent/general/body_basics/spleen_lymphatic.html

Lymphatic System

http://www.google.co.za/imgres?start=83&hl=en&sa=X&rlz=1T4LENN_enZA490ZA490&biw=1366&bih=613&tbn=isch&prmd=imvns&tbnid=-flgwTmsqqlNM:&imgrefurl=http://cancerhelp.cancerresearchuk.org/type/hodgkins-lymphoma/about/what-is-hodgkins-lymphoma&docid=sUKIP6oPMYlj-M&imgurl=http://cancerhelp.cancerresearchuk.org/prod_consump/groups/cr_common/%2540cah/%2540gen/documents/image/crukimg_1000img-12066.jpg&w=350&h=431&ei=YdRSUOCpMOSx0QXWr4DABQ&zoom=1&iact=hc&vpx=1106&vpy=249&dur=2671&hovh=249&hovw=202&tx=127&ty=114&sig=107310304455409594391&page=4&tbnh=129&tbnw=105&ndsp=30&ved=1t:429,r:29,s:83,i:96

Lymph Node

http://www.google.co.za/imgres?hl=en&sa=X&rlz=1T4LENN_enZA490ZA490&biw=1366&bih=613&tbn=isch&prmd=imvns&tbnid=y5UPisMY6d3v2M:&imgrefurl=http://www.smartdraw.com/examples/view/non-hodgkin%2Blymphoma%2B-%2Bcell/&docid=r4nBtXE1dXFreM&imgurl=http://wc1.smartdraw.com/examples/content/Examples/10_Healthcare/Cancer_Illustrations/Non-Hodgkin_Lymphoma_-_Cell_L.jpg&w=842&h=627&ei=RNRSUM_6O9DY0QX1vYDABQ&zoom=1&iact=rc&dur=527&sig=107310304455409594391&page=2&tbnh=131&tbnw=175&start=23&ndsp=29&ved=1t:429,r:19,s:23,i:206&tx=110&ty=82

Lymphoma Association UK

<http://www.lymphomas.org.uk/sites/default/files/pdfs/Angioimmunoblastic-T-cell-lymphoma.pdf>

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

October 2020

Lymphomainfo.net

<http://www.lymphomainfo.net/nhl/classify.html>
<http://www.lymphomainfo.net/nhl/types/t-ail.html>

Lymphoma Research Foundation

<http://www.lymphoma.org/site/pp.asp?c=bkLTkaOQLmK8E&b=6300145>

MacMillan Cancer support

<http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Lymphomanon-Hodgkin/TypesofNHL/Burkitt.aspx>

Matsuki, E. & Younes, A. 2016. Checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin Lymphoma. *Curr Treat Options Oncol.* 2016 Jun;17(6):31. doi: 10.1007/s11864-016-0401-9.

Medscape

<http://emedicine.medscape.com/article/1099386-overview#aw2aab6b4>

Merseyside & Cheshire Cancer Network

<http://www.mccn.nhs.uk/userfiles/documents/Guidelines%20for%20treatment%20of%20Burkitts%20Lymphoma%20DEC%202010.pdf>

Mayo Clinic

<http://www.mayoclinic.com/health/hodgkins-disease/DS00186/DSECTION=risk-factors>

Medline Plus

<http://www.nlm.nih.gov/medlineplus/ency/article/001308.htm>

National Cancer Institute

<http://www.training.seer.cancer.gov/lymphoma/abstract-code-stage/>

Non-Hodgkin's Lymphoma

https://www.google.co.za/search?q=non-hodgkin%27s+lymphoma&source=lnms&tbn=isch&sa=X&ei=AGCZU8q1KsLD7Aax9IH4Aw&sqi=2&ved=0CAYQ_AUoAQ&biw=1517&bih=714&dpr=0.9#facrc=_&imgdii=kKB9P4GyA_Fu3M%3A%3B2h1pJ-GD7YW-PM%3BkKB9P4GyA_Fu3M%3A&imgsrc=kKB9P4GyA_Fu3M%253A%3BNDhAy5EHR6ijXM%3Bhttp%253A%252F%252Fwww.cixip.com%252FPublic%252Fkindeditor%252Fattached%252Fimage%252F20120925%252F20120925100954_31690.jpg%3Bhttp%253A%252F%252Fwww.cixip.com%252Findex.php%252Fpage%252Fcontent%252Fid%252F613%3B537%3B600

Piris, M.A., Medeiros, L.J. & Chang, K-C. 2020. Hodgkin Lymphoma: a review of pathological features and recent advances in pathogenesis. *Pathology.* 2020 Jan;52(1):154-165.

PubMed Health. Hodgkin's Lymphoma.

<http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001606/>
<http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001607/>
<http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002285/>

Rodriguez-Justo, M., Attygalle, A.D., Munson, P., Roncador, G, Maragiotti, T. & Pirisw, M.A. 2009. Antioimmunoblastic T-Cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers. *Modern Pathology*, 22:753-761. doi:10.1038/modpathol.2009.12; published online 27 March 2009

Spina, V. & Rossi, D. 2019. Liquid biopsy in tissue-born lymphomas. *Swiss Med Wkly.* 2019 Jan 23;149:w14709. doi: smw.2019.14709. eCollection 2019 Jan 14.

The Burkitt's Lymphoma Society

<http://burkittslymphomasociety.com/>

The Immune System

<http://www.humanvitaminhealth.com/yourimmunesystem.html>

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

October 2020

University of Maryland Medical Center

http://www.umm.edu/patiented/articles/what_risk_factors_non-hodgkins_lymphomas_000084_2.htm

WebMD

<http://www.webmd.com/cancer/burkitt-lymphoma-prognosis-diagnosis-treatments>

<http://www.webmd.com/cancer/lymphoma/news/20150318/new-drug-may-help-keep-hodgkin-lymphoma-at-bay>

Researched and Authored by Prof Michael C Herbst

[D Litt et Phil (Health Studies); D N Ed; M Art et Scien; B A Cur; Dip Occupational Health; Dip Genetic Counselling; Diagnostic Radiographer; Dip Audiometry and Noise Measurement; Medical Ethicist]

Approved by Ms Elize Joubert, Chief Executive Officer [BA Social Work (cum laude); MA Social Work]

October 2020